Avantor (AVTR) Q1 FY26 earnings call

Avantor's Q1 FY26 results surpassed expectations, driven by improved execution in its BioScience and Medtech product segments and the positive early impact of its "Revival" program. The company reaffirmed its full-year guidance, anticipating VWR's growth rate bottomed in Q1 and BMP's will bottom in Q2, positioning Avantor for a return to positive organic revenue growth in the second half of the year despite emerging inflationary headwinds. Leadership changes and operational enhancements are central to this turnaround.